Samsung Organoids
Samsung Organoids is a patient-derived organoid platform that supports
precision drug screening, drug discovery, and translational research. The platform
uses tumor organoid models, AI-based predictive analysis, and multi-omics data
to help biopharma companies evaluate drug response, identify targets, and
accelerate early-stage oncology research.
Patient-Derived Organoids for Precision Drug Screening
Our patient-derived tumor organoids serve as 3D cancer models that replicate individual tumor biology, providing a powerful platform for precision oncology. We deliver organoid drug screening services across colorectal, lung, liver, gastric, and breast cancers to identify high-efficacy compounds with strong clinical correlation.
These advanced tumor organoid models enable researchers to predict therapeutic outcomes more accurately, supporting early Process Development and data-driven decision-making across the Late Discovery stage.
- Patient
- Cancer Tissue
- Samsung Organoids
- Organoid Biobank
Organoid-Based Drug Discovery and Research Services
Samsung Organoids support a seamless CDMO journey from early discovery to clinical translation. Through extensive biological datasets and predictive analysis, our organoid services provide critical insights that enhance success rates during lead identification, preclinical development, and clinical evaluation.
From target validation to patient stratification, our organoid technology platform strengthens decision-making in Biopharma Manufacturing and Analytical Development, ensuring translational relevance and clinical efficiency.
-
Research / Early Discovery
Evaluate efficacy to support drug evaluation and
lead selection, enhancing clinical success rates -
Late Discovery /
CDO -
Clinical
Manufacturing -
Commercial
Manufacturing
-
-
Target Discovery
-
- Therapeutic target validation
- Disease-relevant organoids
model development
-
-
-
Lead Selection
-
- Lead identification
- Efficacy examination
-
-
-
Preclinical
Development -
- Biomarker identification
- Drug selection support based
on multi-modal data
-
-
-
Clinical Trial
-
- Indication expansion
- Patient stratification for clinical trial
-
Samsung Organoids Summary
- Samsung Organoids supports patient-derived organoid drug screening for precision oncology research.
- Core services include drug response testing, target validation, lead identification, and biomarker discovery.
- The platform combines tumor organoid models, AI-based predictive analysis, and multi-omics datasets.
- Organoid-based research services support early drug discovery, preclinical evaluation, and translational research.
Features of Samsung Organoids
Samsung Organoids accelerates your drug development program with reliable, data-driven predictive models and comprehensive analytical support. Our services combine biological precision, reproducibility, and scalability to enable efficient progression through discovery and development.
-
-
Rapid, Bespoke
Organoid Support - Accelerate market entry with organoids designed to match specific therapeutic targets and development stages. Each organoid model is optimized to support strategic decisions across Non-GMP / CGMP Manufacturing pipelines.
-
-
-
Comprehensive Analysis
and Screening - Gain deeper biological insights through multi-modal tumor datasets, including WES, RNA-seq, and matched patient profiles. This integrated analysis strengthens Analytical Testing accuracy and enhances target discovery outcomes.
-
-
-
Reproducible,
High-Quality Data - All organoid data are generated and validated using standardized workflows for quality and consistency. Our robust analytical framework supports confident decision-making across Drug Product Manufacturing and Drug Substance Manufacturing processes.
-
Related Content